董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Angela Holtham | 女 | Director | -- | 6.40万美元 | 未持股 | 2020-12-31 |
| Bernd R. Seizinger | 男 | Director | 67 | 未披露 | 未持股 | 2020-12-31 |
| Deborah M. Brown | 女 | Director | -- | 未披露 | 未持股 | 2020-12-31 |
| Leonard Kruimer | 男 | Director | 67 | 未披露 | 未持股 | 2020-12-31 |
| William G. Rice | 男 | Director | 65 | 未披露 | 未持股 | 2020-12-31 |
| Matthew C. Coffey | 男 | President and Chief Executive Officer and Director | -- | 148.94万美元 | 未持股 | 2020-12-31 |
| Wayne Pisano | 男 | Chair of the Board | 69 | 3.73万美元 | 未持股 | 2020-12-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Andrew de Guttadauro | 男 | Global Head of Business Development, President, Oncolytics Biotech (U.S.) Inc. | -- | 90.35万美元 | 未持股 | 2020-12-31 |
| Allison Hagerman | 女 | Vice President, Product Development | -- | 73.83万美元 | 未持股 | 2020-12-31 |
| Thomas C. Heineman | 男 | Global Head of Clinical Development and Operations | -- | 64.10万美元 | 未持股 | 2020-12-31 |
| Matthew C. Coffey | 男 | President and Chief Executive Officer and Director | -- | 148.94万美元 | 未持股 | 2020-12-31 |
| Kirk J. Look | 男 | Chief Financial Officer | -- | 112.69万美元 | 未持股 | 2020-12-31 |
董事简历
中英对照 | 中文 | 英文- Angela Holtham
-
Angela Holtham，她担任加拿大治理职位，包括Ontario Financing Authority的董事会成员、IBI Group公司的董事会董事、CMA Canada的董事会董事、Plexxus公司的资源与审计委员会成员。从全职工作退休前，她曾任职The Hospital for Sick Children（位于多伦多）8年，担任财务副总裁兼首席财务官。此前，她曾担任营利性和非营利部门的多种职务，包括任职Nabisco Canada公司20年，并在最后5年担任高级副总裁兼首席财务官。
Angela Holtham held a number of financial positions over a 19-year career with the Canadian subsidiary of Nabisco Inc., rising to become Senior Vice President and Chief Financial Officer. In 2002 she joined Toronto, Ontario-based Hospital for Sick Children as Vice President, Finance and Chief Financial Officer, a position she held for eight years. Through her career she has participated in myriad initiatives ranging from traditional finance functions and operations oversight to intellectual property portfolio management and mergers and acquisitions. Ms. Holtham is an FCPA, FCMA, holds an MBA from the University of Toronto - Rotman School of Management and has completed the Institute of Corporate Directors Designation ICD.D. - Angela Holtham，她担任加拿大治理职位，包括Ontario Financing Authority的董事会成员、IBI Group公司的董事会董事、CMA Canada的董事会董事、Plexxus公司的资源与审计委员会成员。从全职工作退休前，她曾任职The Hospital for Sick Children（位于多伦多）8年，担任财务副总裁兼首席财务官。此前，她曾担任营利性和非营利部门的多种职务，包括任职Nabisco Canada公司20年，并在最后5年担任高级副总裁兼首席财务官。
- Angela Holtham held a number of financial positions over a 19-year career with the Canadian subsidiary of Nabisco Inc., rising to become Senior Vice President and Chief Financial Officer. In 2002 she joined Toronto, Ontario-based Hospital for Sick Children as Vice President, Finance and Chief Financial Officer, a position she held for eight years. Through her career she has participated in myriad initiatives ranging from traditional finance functions and operations oversight to intellectual property portfolio management and mergers and acquisitions. Ms. Holtham is an FCPA, FCMA, holds an MBA from the University of Toronto - Rotman School of Management and has completed the Institute of Corporate Directors Designation ICD.D.
- Bernd R. Seizinger
-
Bernd R. Seizinger，自2015年起担任Aprea Therapeutics, Inc.董事会成员。他是多家公司的董事会成员，包括Opsona Dublin, Ireland, Agennix AG （Princeton, NJ；休斯顿，德克萨斯州；德国慕尼黑）和TriMod有限公司（爱尔兰都柏林）。他是Opsona Ltd.的主席。以及Trimod有限公司的代理主席。从1998年到2009年，他担任GPC Biotech（与Agennix AG合并之前）的总裁兼首席执行官。在他的公司任命之前，他在麻省总医院和哈佛医学院。
Bernd R. Seizinger,has served as a member of board of directors of Aprea Therapeutics, Inc. since 2015. Dr. Seizinger is a board member in a number of public and private biotech companies in the United States, Europe, and Canada, including Aptose Biosciences Inc., Oxford BioTherapeutics Ltd., Nykode Therapeutics ASA, BioInvent International AB, Oncolytics Biotech Inc. and CryptoMedix Inc. Previously, Dr. Seizinger was President and Chief Executive Officer of GPC Biotech, VP Oncology Drug Discovery at Bristol-Myers Squibb Company, and Executive VP and Chief Scientific Officer at Genome Therapeutics. Prior to his corporate appointments, he held senior faculty positions at Massachusetts Harvard Medical School, Massachusetts General Hospital and Princeton University. - Bernd R. Seizinger，自2015年起担任Aprea Therapeutics, Inc.董事会成员。他是多家公司的董事会成员，包括Opsona Dublin, Ireland, Agennix AG （Princeton, NJ；休斯顿，德克萨斯州；德国慕尼黑）和TriMod有限公司（爱尔兰都柏林）。他是Opsona Ltd.的主席。以及Trimod有限公司的代理主席。从1998年到2009年，他担任GPC Biotech（与Agennix AG合并之前）的总裁兼首席执行官。在他的公司任命之前，他在麻省总医院和哈佛医学院。
- Bernd R. Seizinger,has served as a member of board of directors of Aprea Therapeutics, Inc. since 2015. Dr. Seizinger is a board member in a number of public and private biotech companies in the United States, Europe, and Canada, including Aptose Biosciences Inc., Oxford BioTherapeutics Ltd., Nykode Therapeutics ASA, BioInvent International AB, Oncolytics Biotech Inc. and CryptoMedix Inc. Previously, Dr. Seizinger was President and Chief Executive Officer of GPC Biotech, VP Oncology Drug Discovery at Bristol-Myers Squibb Company, and Executive VP and Chief Scientific Officer at Genome Therapeutics. Prior to his corporate appointments, he held senior faculty positions at Massachusetts Harvard Medical School, Massachusetts General Hospital and Princeton University.
- Deborah M. Brown
-
DeborahM.Brown是Accelera Canada（一家专业咨询公司，协助美国和欧洲新兴的生物制药企业开发和实施加拿大市场战略）的管理合伙人。2000年至2014年，她在EMD Serono逐步担任高级职位，包括公司美国业务的神经免疫学执行Vice President，以及公司加拿大业务的总裁兼董事总经理。2012年，Brown女士担任National Pharmaceutical Organization Now Innovative Medicines Canada的主席，并于2007年至2014年担任其董事会成员。她目前任职于Life Sciences Ontario、the HBSPCA and Cardiol Therapeutics、Oncolytics Biotech Inc、Sernova Corp的董事会。Brown女士拥有University of Western Ontario’s Ivey School of Business工商管理硕士学位，荣誉学士学位。毕业于盖尔夫大学，并完成了香港大学，欧洲工商管理学院和西北大学凯洛格管理学院的默克执行发展课程。她最近完成了the Institute of Corporate Directors Designation（ICD.D）。
Deborah M. Brown is the Managing Partner at Accelera Canada Ltd., a specialty consultancy firm that assists emerging biopharma ventures in the United States and Europe with the development and implementation of Canadian market strategies. She held progressively senior roles at EMD Serono from 2000 to 2014 including Executive Vice President of Neuroimmunology for the company's U.S. operations, and President and Managing Director of the company's Canadian operations. In 2012 Ms. Brown was Chair of the National Pharmaceutical Organization now Innovative Medicines Canada and served on its Board of Directors from 2007 to 2014. She currently sits on the Boards of the HBSPCA, Cardiol Therapeutics, Oncolytics Biotech Inc, and Sernova Corp. Ms. Brown holds an MBA from University of Western Ontario's Ivey School of Business, an Hons B.Sc. from the University of Guelph. She most recently completed the Institute of Corporate Directors Designation (ICD.D). - DeborahM.Brown是Accelera Canada（一家专业咨询公司，协助美国和欧洲新兴的生物制药企业开发和实施加拿大市场战略）的管理合伙人。2000年至2014年，她在EMD Serono逐步担任高级职位，包括公司美国业务的神经免疫学执行Vice President，以及公司加拿大业务的总裁兼董事总经理。2012年，Brown女士担任National Pharmaceutical Organization Now Innovative Medicines Canada的主席，并于2007年至2014年担任其董事会成员。她目前任职于Life Sciences Ontario、the HBSPCA and Cardiol Therapeutics、Oncolytics Biotech Inc、Sernova Corp的董事会。Brown女士拥有University of Western Ontario’s Ivey School of Business工商管理硕士学位，荣誉学士学位。毕业于盖尔夫大学，并完成了香港大学，欧洲工商管理学院和西北大学凯洛格管理学院的默克执行发展课程。她最近完成了the Institute of Corporate Directors Designation（ICD.D）。
- Deborah M. Brown is the Managing Partner at Accelera Canada Ltd., a specialty consultancy firm that assists emerging biopharma ventures in the United States and Europe with the development and implementation of Canadian market strategies. She held progressively senior roles at EMD Serono from 2000 to 2014 including Executive Vice President of Neuroimmunology for the company's U.S. operations, and President and Managing Director of the company's Canadian operations. In 2012 Ms. Brown was Chair of the National Pharmaceutical Organization now Innovative Medicines Canada and served on its Board of Directors from 2007 to 2014. She currently sits on the Boards of the HBSPCA, Cardiol Therapeutics, Oncolytics Biotech Inc, and Sernova Corp. Ms. Brown holds an MBA from University of Western Ontario's Ivey School of Business, an Hons B.Sc. from the University of Guelph. She most recently completed the Institute of Corporate Directors Designation (ICD.D).
- Leonard Kruimer
-
Leonard Kruimer在公司财务、规划和战略方面有30多年的经验，包括在私营和公开上市的生物技术和生命科学公司担任20多年的高级管理职务。值得注意的是，从1998年到2011年Crucell被强生公司收购，Kruimer先生担任Crucell的首席财务官和执行委员会成员。任职期间，他曾领导公司的融资活动，并促成Crucell公司以4.5亿美元战略收购总部位于瑞士的Berna Biotech公司。目前，Kruimer先生担任Zealand Pharma NASDAQ:ZEAL的独立董事兼审计委员会主席，是BioInvent AB（OMXS:BINV）的董事会主席，并在位于阿姆斯特丹的私募股权公司Karmijn Kapitaal Investments的投资咨询委员会任职。此前，他曾担任SkylinedX公司（DNA诊断公司）的首席财务官，也曾担任Profibrix公司的董事会主席（从2011年到2013年公司被The Medicines Company（NASDAQ:MDCO）收购）。2014年Kruimer先生担任Dutch Biotech BBB Therapeutics的临时首席执行官。任职Crucell公司之前，Kruimer曾担任Tip Europe公司（GE Capital公司）的董事总经理。他曾担任McKinsey&Company的顾问，并在纽约Price Waterhouse开始他的职业生涯。Kruimer先生拥有哈佛商学院（Harvard Business School）工商管理硕士学位，是纽约州的注册会计师。
Leonard Kruimer has over 30 years experience in accounting, corporate finance, and strategy, in senior management positions in private and publicly listed life science companies. Mr. Kruimer served as CFO and Executive Committee Member of Crucell from 1998 through 2011 when Crucell was acquired by JNJ. During his tenure, he led financing activities of the company and contributed to Crucell's strategic acquisition of Swiss-based Berna Biotech. Currently, Mr. Kruimer serves as independent director and Chairman of the Audit Committee for Zealand Pharma Nasdaq: ZEAL, and Chairman of the Board of BioInvent AB (OMXS: BINV). He is a director of Advent Int. Global Investments and advisor to private equity firm Karmijn Kapitaal Investments. Previously, he was CFO of SkylineDx, a DNA diagnostics company and Chairman of ProFibrix through its acquisition by The Medicines Company (Nasdaq: MDCO) in 2013. Mr. Kruimer held various executive board positions on an interim basis. Prior to Crucell, Mr. Kruimer held senior executive positions at TIP Europe, a GE Capital company and Continental Can Europe. He was a consultant with McKinsey and started his career at Price Waterhouse in New York. Mr. Kruimer holds an MBA from Harvard, a BA in accounting and finance from University of Massachusetts and is a CPA in New York State. - Leonard Kruimer在公司财务、规划和战略方面有30多年的经验，包括在私营和公开上市的生物技术和生命科学公司担任20多年的高级管理职务。值得注意的是，从1998年到2011年Crucell被强生公司收购，Kruimer先生担任Crucell的首席财务官和执行委员会成员。任职期间，他曾领导公司的融资活动，并促成Crucell公司以4.5亿美元战略收购总部位于瑞士的Berna Biotech公司。目前，Kruimer先生担任Zealand Pharma NASDAQ:ZEAL的独立董事兼审计委员会主席，是BioInvent AB（OMXS:BINV）的董事会主席，并在位于阿姆斯特丹的私募股权公司Karmijn Kapitaal Investments的投资咨询委员会任职。此前，他曾担任SkylinedX公司（DNA诊断公司）的首席财务官，也曾担任Profibrix公司的董事会主席（从2011年到2013年公司被The Medicines Company（NASDAQ:MDCO）收购）。2014年Kruimer先生担任Dutch Biotech BBB Therapeutics的临时首席执行官。任职Crucell公司之前，Kruimer曾担任Tip Europe公司（GE Capital公司）的董事总经理。他曾担任McKinsey&Company的顾问，并在纽约Price Waterhouse开始他的职业生涯。Kruimer先生拥有哈佛商学院（Harvard Business School）工商管理硕士学位，是纽约州的注册会计师。
- Leonard Kruimer has over 30 years experience in accounting, corporate finance, and strategy, in senior management positions in private and publicly listed life science companies. Mr. Kruimer served as CFO and Executive Committee Member of Crucell from 1998 through 2011 when Crucell was acquired by JNJ. During his tenure, he led financing activities of the company and contributed to Crucell's strategic acquisition of Swiss-based Berna Biotech. Currently, Mr. Kruimer serves as independent director and Chairman of the Audit Committee for Zealand Pharma Nasdaq: ZEAL, and Chairman of the Board of BioInvent AB (OMXS: BINV). He is a director of Advent Int. Global Investments and advisor to private equity firm Karmijn Kapitaal Investments. Previously, he was CFO of SkylineDx, a DNA diagnostics company and Chairman of ProFibrix through its acquisition by The Medicines Company (Nasdaq: MDCO) in 2013. Mr. Kruimer held various executive board positions on an interim basis. Prior to Crucell, Mr. Kruimer held senior executive positions at TIP Europe, a GE Capital company and Continental Can Europe. He was a consultant with McKinsey and started his career at Price Waterhouse in New York. Mr. Kruimer holds an MBA from Harvard, a BA in accounting and finance from University of Massachusetts and is a CPA in New York State.
- William G. Rice
-
William G. Rice自2013年起担任Aptose Biosciences Inc.的董事长、总裁兼首席执行官，2013年10月加入Lorus，担任董事长兼首席执行官。从2003年到2013年，他担任Cylene Pharmaceuticals Inc.的董事长、总裁和首席执行官，此前他是Achillion Pharmaceuticals, Inc.的创始人、总裁、首席执行官和董事。他还曾担任the National Cancer Institute-Frederick Cancer Research and Development Center的高级科学家和药物机制实验室负责人，以及埃默里医学院（Emory School of Medicine）儿童血液学和肿瘤学部门的教员。Rice博士持有Emory University Laney Graduate School的生物化学博士学位，曾是the University of Michigan Medical Center的内科血液学和肿瘤学部门的博士后实习生。
William G. Rice has held the position of Chairman, President and Chief Executive Officer of Aptose Biosciences Inc. since 2013. From 2003 to 2013 he served as Chairman, President and Chief Executive Officer of Cylene Pharmaceutics Inc., prior to which he was the Founder, President, Chief Executive Officer and Director of Achillion Pharmaceuticals, Inc. He has also served as Senior Scientist and Head of the Drug Mechanism Laboratory at the National Cancer Institute-Frederick Cancer Research and Development Center, and as a faculty member in the Division of Pediatric Hematology and Oncology at Emory School of Medicine. Dr. Rice holds a PhD in biochemistry from Emory University Laney Graduate School and was a post-doctoral trainee in the Department of Internal Medicine, Division of Hematology and Oncology at the University of Michigan Medical Center. - William G. Rice自2013年起担任Aptose Biosciences Inc.的董事长、总裁兼首席执行官，2013年10月加入Lorus，担任董事长兼首席执行官。从2003年到2013年，他担任Cylene Pharmaceuticals Inc.的董事长、总裁和首席执行官，此前他是Achillion Pharmaceuticals, Inc.的创始人、总裁、首席执行官和董事。他还曾担任the National Cancer Institute-Frederick Cancer Research and Development Center的高级科学家和药物机制实验室负责人，以及埃默里医学院（Emory School of Medicine）儿童血液学和肿瘤学部门的教员。Rice博士持有Emory University Laney Graduate School的生物化学博士学位，曾是the University of Michigan Medical Center的内科血液学和肿瘤学部门的博士后实习生。
- William G. Rice has held the position of Chairman, President and Chief Executive Officer of Aptose Biosciences Inc. since 2013. From 2003 to 2013 he served as Chairman, President and Chief Executive Officer of Cylene Pharmaceutics Inc., prior to which he was the Founder, President, Chief Executive Officer and Director of Achillion Pharmaceuticals, Inc. He has also served as Senior Scientist and Head of the Drug Mechanism Laboratory at the National Cancer Institute-Frederick Cancer Research and Development Center, and as a faculty member in the Division of Pediatric Hematology and Oncology at Emory School of Medicine. Dr. Rice holds a PhD in biochemistry from Emory University Laney Graduate School and was a post-doctoral trainee in the Department of Internal Medicine, Division of Hematology and Oncology at the University of Michigan Medical Center.
- Matthew C. Coffey
-
Matthew C. Coffey，2008年12月以来，他一直担任公司的首席运营官。从1999年4月到2008年12月，他担任公司其他高级管理职位，是Oncolytics公司的创始人。
Matthew C. Coffey completed his doctorate degree in oncology at the University of Calgary with a focus on the oncolytic capabilities of the reovirus. The results of his research have been published in various respected scientific journals, including Science, Human Gene Therapy, and The EMBO Journal. Dr. Coffey took over as Chief Executive Officer in late 2016 prior to which he was Chief Operating Officer since December 2008. Since co-founding Oncolytics he has also held the positions of Chief Scientific Officer from December 2004 to December 2008 Vice-President of Product Development from July 1999 to December 2004 and Chief Financial Officer from September 1999 to May 2000. - Matthew C. Coffey，2008年12月以来，他一直担任公司的首席运营官。从1999年4月到2008年12月，他担任公司其他高级管理职位，是Oncolytics公司的创始人。
- Matthew C. Coffey completed his doctorate degree in oncology at the University of Calgary with a focus on the oncolytic capabilities of the reovirus. The results of his research have been published in various respected scientific journals, including Science, Human Gene Therapy, and The EMBO Journal. Dr. Coffey took over as Chief Executive Officer in late 2016 prior to which he was Chief Operating Officer since December 2008. Since co-founding Oncolytics he has also held the positions of Chief Scientific Officer from December 2004 to December 2008 Vice-President of Product Development from July 1999 to December 2004 and Chief Financial Officer from September 1999 to May 2000.
- Wayne Pisano
-
Wayne Pisano， 他拥有工商管理硕士学位。他拥有超过30年的制药行业高管的任职经验，并被世界疫苗大会（World Vaccine Congress）评为2010年的年度制药公司执行官。他目前担任VaxInnate公司（一个私营生物技术公司）的总裁兼首席执行官。他是Sanofi Pasteur公司（世界上最大的疫苗公司之一）的前任总裁兼首席执行官。加入Sanofi Pasteur公司之前，他曾任职Novartis公司（原名Sandoz公司）11年。他持有圣约翰费舍尔大学（Saint John Fisher College）（位于纽约）的生物学学士学位，以及俄亥俄州代顿大学（University of Dayton， Ohio）的工商管理硕士学位。
Wayne Pisano,has served as a member of Altimmune, Inc. Board of Directors since August 2018. Mr. Pisano also has served on the board of directors of Oncolytics Biotech Inc. (Nasdaq: ONCY), a biotechnology company, since May 2013. Mr. Pisano served on the board of directors of Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company, from April 2018 until April 2023 when it was acquired by Sanofi, and IMV INC. (Nasdaq: IMV) a bio pharmaceutical company from October 2011 until March 2021. Mr. Pisano served as president and Chief Executive Officer of VaxInnate Corporation, a biotechnology company, from January 2012 until November 2016. Mr. Pisano joined Sanofi Pasteur in 1997 and was promoted to President and Chief Executive Officer in 2007, the position he successfully held until his retirement in 2011. He has a Bachelor of Science in biology from St. John Fisher College, New York and an MBA from the University of Dayton, Ohio. - Wayne Pisano， 他拥有工商管理硕士学位。他拥有超过30年的制药行业高管的任职经验，并被世界疫苗大会（World Vaccine Congress）评为2010年的年度制药公司执行官。他目前担任VaxInnate公司（一个私营生物技术公司）的总裁兼首席执行官。他是Sanofi Pasteur公司（世界上最大的疫苗公司之一）的前任总裁兼首席执行官。加入Sanofi Pasteur公司之前，他曾任职Novartis公司（原名Sandoz公司）11年。他持有圣约翰费舍尔大学（Saint John Fisher College）（位于纽约）的生物学学士学位，以及俄亥俄州代顿大学（University of Dayton， Ohio）的工商管理硕士学位。
- Wayne Pisano,has served as a member of Altimmune, Inc. Board of Directors since August 2018. Mr. Pisano also has served on the board of directors of Oncolytics Biotech Inc. (Nasdaq: ONCY), a biotechnology company, since May 2013. Mr. Pisano served on the board of directors of Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company, from April 2018 until April 2023 when it was acquired by Sanofi, and IMV INC. (Nasdaq: IMV) a bio pharmaceutical company from October 2011 until March 2021. Mr. Pisano served as president and Chief Executive Officer of VaxInnate Corporation, a biotechnology company, from January 2012 until November 2016. Mr. Pisano joined Sanofi Pasteur in 1997 and was promoted to President and Chief Executive Officer in 2007, the position he successfully held until his retirement in 2011. He has a Bachelor of Science in biology from St. John Fisher College, New York and an MBA from the University of Dayton, Ohio.
高管简历
中英对照 | 中文 | 英文- Andrew de Guttadauro
Andrew de Guttadauro拥有超过25年的生物制药商业化和商业开发经验。他曾担任领先的制药和生物技术公司的执行和高级职务，致力于全球发达和新兴市场的举措。de Guttadauro在TAP Pharmaceuticals开始他的职业生涯，支持重磅药物Lupron®；和Prevacid®；的上市。他在Amgen担任多个营销职位，为Enbrel&174；，Aranesp&174；和Epogen&174；的成功做出了贡献，之后加入MedImmune领导Flumist&174；吸入流感疫苗的营销工作。在监督Zevalin®；的商业开发（Zevalin®；是美国批准使用的第一个放射免疫治疗产品）两年后，de Guttadauro先生担任Biogen Idec的战略高级总监。他随后担任Vical公司的企业发展Vice President，支持Allovectin®；分销协议的执行。在加入Oncolytics之前，De Guttadauro先生是1798Consultants Inc.的负责人，该公司是一家梦百合咨询公司，为领先和新兴的生物制药公司提供商业化、市场准入和合规战略建议。de Guttadauro在西点军校（United States Military Academy at West Point）获得工程学理学学士学位。
Andrew de Guttadauro has more than 25 years of biopharmaceutical commercialization and business development experience. He has held executive and senior-level positions at leading pharmaceutical and biotechnology companies, working on initiatives across both developed and emerging markets globally.Mr. de Guttadauro began his career at TAP Pharmaceuticals, supporting the launch of blockbuster drugs, Lupron® and Prevacid®. He held a variety of marketing positions at Amgen, contributing to the success of Enbrel®, Aranesp®, and Epogen® before joining MedImmune to lead marketing efforts for the FluMist® inhaled influenza vaccine. Following a two-year assignment overseeing the commercial development of Zevalin®, the first radioimmunotherapy product approved for use in the United States, Mr. de Guttadauro took on the role of Senior Director of Strategy at Biogen Idec. He then served as Vice President of Corporate Development at Vical, supporting the execution of distribution agreements for Allovectin®. Prior to joining Oncolytics, Mr. de Guttadauro was a Principal at 1798 Consultants Inc., a healthcare consulting firm providing commercialization, market access, and compliance strategic advice to leading and emerging biopharmaceutical companies.- Andrew de Guttadauro拥有超过25年的生物制药商业化和商业开发经验。他曾担任领先的制药和生物技术公司的执行和高级职务，致力于全球发达和新兴市场的举措。de Guttadauro在TAP Pharmaceuticals开始他的职业生涯，支持重磅药物Lupron®；和Prevacid®；的上市。他在Amgen担任多个营销职位，为Enbrel&174；，Aranesp&174；和Epogen&174；的成功做出了贡献，之后加入MedImmune领导Flumist&174；吸入流感疫苗的营销工作。在监督Zevalin®；的商业开发（Zevalin®；是美国批准使用的第一个放射免疫治疗产品）两年后，de Guttadauro先生担任Biogen Idec的战略高级总监。他随后担任Vical公司的企业发展Vice President，支持Allovectin®；分销协议的执行。在加入Oncolytics之前，De Guttadauro先生是1798Consultants Inc.的负责人，该公司是一家梦百合咨询公司，为领先和新兴的生物制药公司提供商业化、市场准入和合规战略建议。de Guttadauro在西点军校（United States Military Academy at West Point）获得工程学理学学士学位。
- Andrew de Guttadauro has more than 25 years of biopharmaceutical commercialization and business development experience. He has held executive and senior-level positions at leading pharmaceutical and biotechnology companies, working on initiatives across both developed and emerging markets globally.Mr. de Guttadauro began his career at TAP Pharmaceuticals, supporting the launch of blockbuster drugs, Lupron® and Prevacid®. He held a variety of marketing positions at Amgen, contributing to the success of Enbrel®, Aranesp®, and Epogen® before joining MedImmune to lead marketing efforts for the FluMist® inhaled influenza vaccine. Following a two-year assignment overseeing the commercial development of Zevalin®, the first radioimmunotherapy product approved for use in the United States, Mr. de Guttadauro took on the role of Senior Director of Strategy at Biogen Idec. He then served as Vice President of Corporate Development at Vical, supporting the execution of distribution agreements for Allovectin®. Prior to joining Oncolytics, Mr. de Guttadauro was a Principal at 1798 Consultants Inc., a healthcare consulting firm providing commercialization, market access, and compliance strategic advice to leading and emerging biopharmaceutical companies.
- Allison Hagerman
Allison Hagerman.Hagerman女士是一名专注于生物技术的专业工程师，她于2010年加入Oncolytics，自那时以来一直是Oncolytics产品开发项目进展的组成部分。在被任命为产品开发Vice President之前，Hagerman女士于2013年至2017年担任制造和工程部总监，并于2010年至2013年担任项目经理，在此期间，她领导了Pelareorep原料药的工艺性能认证。Hagerman女士是专业工程师P.Eng.，APEGA和项目管理专业人员（PMP，PMI）。她持有the University of Calgary的生物医学技术硕士学位（MBT），以及B.SC.。化学工程和生物科学学位。
Allison Hagerman joined Oncolytics in 2010 and has been integral to the progress of its product development program ever since. Prior to being appointed as Vice President of Product Development, Ms. Hagerman was the Director, Manufacturing and Engineering from 2013-2017 and Project Manager from 2010-2013 during which time she led the process performance qualification for pelareorep drug substance. Ms. Hagerman is a Professional Engineer P.Eng., APEGA and Project Management Professional (PMP, PMI). She holds a Master of Biomedical Technology (MBT) degree from the University of Calgary, and B.Sc. degrees in both Chemical Engineering and Biological Sciences.- Allison Hagerman.Hagerman女士是一名专注于生物技术的专业工程师，她于2010年加入Oncolytics，自那时以来一直是Oncolytics产品开发项目进展的组成部分。在被任命为产品开发Vice President之前，Hagerman女士于2013年至2017年担任制造和工程部总监，并于2010年至2013年担任项目经理，在此期间，她领导了Pelareorep原料药的工艺性能认证。Hagerman女士是专业工程师P.Eng.，APEGA和项目管理专业人员（PMP，PMI）。她持有the University of Calgary的生物医学技术硕士学位（MBT），以及B.SC.。化学工程和生物科学学位。
- Allison Hagerman joined Oncolytics in 2010 and has been integral to the progress of its product development program ever since. Prior to being appointed as Vice President of Product Development, Ms. Hagerman was the Director, Manufacturing and Engineering from 2013-2017 and Project Manager from 2010-2013 during which time she led the process performance qualification for pelareorep drug substance. Ms. Hagerman is a Professional Engineer P.Eng., APEGA and Project Management Professional (PMP, PMI). She holds a Master of Biomedical Technology (MBT) degree from the University of Calgary, and B.Sc. degrees in both Chemical Engineering and Biological Sciences.
- Thomas C. Heineman
Thomas C.Heineman为Oncolytics带来了20多年领导临床开发项目的经验，包括在生物制药行业的14年。最近，Heineman博士担任Denovo Biopharma的高级副总裁兼临床开发主管。在Denovo任职之前，他曾担任Genocea Biosciences和Halozyme Therapeutics的副总裁兼临床开发主管，在那里他也曾担任转化医学主管，并监管乳腺癌和胰腺癌等适应症的临床试验。Heineman博士的经验进一步扩展到大型制药和学术界，因为他曾担任GlaxoSmithKline全球临床研究与开发的高级总监，以及Saint Louis University School of Medicine的副教授。海尼曼参与撰写了60多份同行评审的出版物，并在包括内科和传染病在内的多个专业领域获得了董事会认证。他完成了在国家卫生研究院的传染病研究金，并在马里兰大学实习和居住。Heineman博士在芝加哥大学获得了医学博士学位，并在那里获得了分子遗传学博士学位。
Thomas C. Heineman,Most recently, Dr. Heineman served as Senior Vice President and Head of Clinical Development at Denovo Biopharma. Prior to his time at Denovo, Dr. Heineman served as Vice President and Head of Clinical Development at Genocea Biosciences and Halozyme Therapeutics, where he was also the Head of Translational Medicine, and oversaw clinical trials in indications such as breast and pancreatic cancer. Dr. Heineman's experience further extends into big pharma and academia, as he has previously held roles as Senior Director, Global Clinical Research and Development at GlaxoSmithKline and as an Associate Professor at the Saint Louis University School of Medicine.Dr. Heineman has co-authored over 60 peer-reviewed publications and is board certified in several specialties, including Internal Medicine and Infectious Diseases. He completed his fellowship in Infectious Diseases at the National Institutes of Health and his internship and residency at the University of Maryland. Dr. Heineman earned his MD at the University of Chicago, where he also received a PhD in molecular genetics.- Thomas C.Heineman为Oncolytics带来了20多年领导临床开发项目的经验，包括在生物制药行业的14年。最近，Heineman博士担任Denovo Biopharma的高级副总裁兼临床开发主管。在Denovo任职之前，他曾担任Genocea Biosciences和Halozyme Therapeutics的副总裁兼临床开发主管，在那里他也曾担任转化医学主管，并监管乳腺癌和胰腺癌等适应症的临床试验。Heineman博士的经验进一步扩展到大型制药和学术界，因为他曾担任GlaxoSmithKline全球临床研究与开发的高级总监，以及Saint Louis University School of Medicine的副教授。海尼曼参与撰写了60多份同行评审的出版物，并在包括内科和传染病在内的多个专业领域获得了董事会认证。他完成了在国家卫生研究院的传染病研究金，并在马里兰大学实习和居住。Heineman博士在芝加哥大学获得了医学博士学位，并在那里获得了分子遗传学博士学位。
- Thomas C. Heineman,Most recently, Dr. Heineman served as Senior Vice President and Head of Clinical Development at Denovo Biopharma. Prior to his time at Denovo, Dr. Heineman served as Vice President and Head of Clinical Development at Genocea Biosciences and Halozyme Therapeutics, where he was also the Head of Translational Medicine, and oversaw clinical trials in indications such as breast and pancreatic cancer. Dr. Heineman's experience further extends into big pharma and academia, as he has previously held roles as Senior Director, Global Clinical Research and Development at GlaxoSmithKline and as an Associate Professor at the Saint Louis University School of Medicine.Dr. Heineman has co-authored over 60 peer-reviewed publications and is board certified in several specialties, including Internal Medicine and Infectious Diseases. He completed his fellowship in Infectious Diseases at the National Institutes of Health and his internship and residency at the University of Maryland. Dr. Heineman earned his MD at the University of Chicago, where he also received a PhD in molecular genetics.
- Matthew C. Coffey
Matthew C. Coffey，2008年12月以来，他一直担任公司的首席运营官。从1999年4月到2008年12月，他担任公司其他高级管理职位，是Oncolytics公司的创始人。
Matthew C. Coffey completed his doctorate degree in oncology at the University of Calgary with a focus on the oncolytic capabilities of the reovirus. The results of his research have been published in various respected scientific journals, including Science, Human Gene Therapy, and The EMBO Journal. Dr. Coffey took over as Chief Executive Officer in late 2016 prior to which he was Chief Operating Officer since December 2008. Since co-founding Oncolytics he has also held the positions of Chief Scientific Officer from December 2004 to December 2008 Vice-President of Product Development from July 1999 to December 2004 and Chief Financial Officer from September 1999 to May 2000.- Matthew C. Coffey，2008年12月以来，他一直担任公司的首席运营官。从1999年4月到2008年12月，他担任公司其他高级管理职位，是Oncolytics公司的创始人。
- Matthew C. Coffey completed his doctorate degree in oncology at the University of Calgary with a focus on the oncolytic capabilities of the reovirus. The results of his research have been published in various respected scientific journals, including Science, Human Gene Therapy, and The EMBO Journal. Dr. Coffey took over as Chief Executive Officer in late 2016 prior to which he was Chief Operating Officer since December 2008. Since co-founding Oncolytics he has also held the positions of Chief Scientific Officer from December 2004 to December 2008 Vice-President of Product Development from July 1999 to December 2004 and Chief Financial Officer from September 1999 to May 2000.
- Kirk J. Look
Kirk J. Look，他是会计师。2012年11月以来，他一直担任该公司的首席财务官。从2003年到2012年11月，他担任该公司的总会计师。
Kirk J. Look is a Chartered Accountant with more than fifteen years of experience in accounting, finance, tax and treasury. Mr. Look joined Oncolytics as the Company's Controller in April 2003 and assumed the role of Chief Financial Officer in November 2012. Prior to joining Oncolytics, from 2000 to April 2003 Mr. Look was Manager of Audit and Assurance Services with Ernst & Young LLP in Canada. From 1998 to the end of 1999 Mr. Look held the positions of Audit Manager and Senior Accountant at Ernst & Young LLP in Chile.- Kirk J. Look，他是会计师。2012年11月以来，他一直担任该公司的首席财务官。从2003年到2012年11月，他担任该公司的总会计师。
- Kirk J. Look is a Chartered Accountant with more than fifteen years of experience in accounting, finance, tax and treasury. Mr. Look joined Oncolytics as the Company's Controller in April 2003 and assumed the role of Chief Financial Officer in November 2012. Prior to joining Oncolytics, from 2000 to April 2003 Mr. Look was Manager of Audit and Assurance Services with Ernst & Young LLP in Canada. From 1998 to the end of 1999 Mr. Look held the positions of Audit Manager and Senior Accountant at Ernst & Young LLP in Chile.